-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, China's pharmaceutical industry has ushered in a golden period of development, and companies have begun to "go global" and participate in international competition
.
For example, from the early export of pharmaceutical raw material intermediates, to the export of chemical preparations and biological drugs, to the overseas authorization of innovative drugs and the US listing of zebutinib in recent years, the international participation of Chinese pharmaceutical companies is constantly escalating
.
Recently, some companies have expressed that they have made new progress in the process of internationalization
.
For example, on October 26, Lunan Pharmaceutical received an approval letter from the US FDA regarding the addition of the Shandong New Times Pharmaceuticals production site to the rosuvastatin calcium tablets ANDA (a brief application for new drugs), marking the ANDA rosuvastatin produced by Lunan Pharmaceuticals Calcium tablets can be sold in the US market
.
The company stated that this is of great significance in the process of Lunan Pharmaceutical's internationalization
.
Data show that rosuvastatin calcium tablets are a selective hydroxymethylglutaryl-coenzyme A reductase inhibitor, which has the characteristics of potent hypolipidemic reduction, fast and safe
.
Hengrui Pharmaceuticals recently stated that in early October, Dr.
Joseph E.
Eid joined Hengrui's overseas team as the chief medical officer of Hengrui US/Europe, mainly responsible for Hengrui's drug development and medical affairs in the European and American regions
.
And this personnel action is considered to be Hengrui's major move to accelerate the process of internationalization
.
When confirming the news, Hengrui Pharmaceuticals stated that the company continues to increase its investment in internationalization.
At present, it has established professional clinical research and development teams in the United States, Europe, Australia, and Japan.
, GPT) mode
.
In addition, Huiyu Pharmaceutical stated that the company relies on the established international sales channels and teams to further advance and refine the work of the international market
.
The company will improve the management system of partners according to the conditions of different countries and regions, strengthen market information collection and analysis capabilities, establish the company's unique global market and a large database of partners, track the development and changes of global medicine, and fully analyze the market environment and ecology of key regions.
Operation model, deep cultivation and meticulous cultivation, to become an international pharmaceutical company
.
The global market is the direction everyone is aiming for
.
According to the industry, in recent years, China's innovative drugs have developed vigorously, which has changed innovative drugs to a large extent.
“We hope that this situation will not only happen in China, but that Chinese pharmaceuticals and bio-innovative drugs can also go to more countries.
, To benefit patients in those countries
.
" In addition, only by "going out" can pharmaceutical companies embrace a broader market
.
According to IQVIA statistics, the size of China's prescription drug market will be about 1.
2 trillion yuan in 2020, and excluding Chinese patent medicines and generic drugs will drop to 70 billion yuan
.
According to evaluate analysis, the global prescription drug market will reach US$904 billion in 2020, or about 5.
8 trillion yuan
.
"Going out is five times or even ten times the market!" Some insiders said
.
Driven by the huge market, more and more companies choose to "go global
.
" For example, in 2017, Nanjing Legend Biotech "handed in" Yang Sen to jointly develop and commercialize CAR-T cell products; in 2020, Tianjing Biotech authorized AbbVie's overseas rights and interests of CD-47 monoclonal antibody; in the same year, Jacques also Reached a cooperation agreement with AbbVie
.
In addition, Baekje, Cinda, Junshi and other companies have also authorized their PD-1 overseas commercialization rights to Novartis, Eli Lilly, Coherus and other multinational pharmaceutical companies to enter the international market
.
.
For example, from the early export of pharmaceutical raw material intermediates, to the export of chemical preparations and biological drugs, to the overseas authorization of innovative drugs and the US listing of zebutinib in recent years, the international participation of Chinese pharmaceutical companies is constantly escalating
.
Recently, some companies have expressed that they have made new progress in the process of internationalization
.
For example, on October 26, Lunan Pharmaceutical received an approval letter from the US FDA regarding the addition of the Shandong New Times Pharmaceuticals production site to the rosuvastatin calcium tablets ANDA (a brief application for new drugs), marking the ANDA rosuvastatin produced by Lunan Pharmaceuticals Calcium tablets can be sold in the US market
.
The company stated that this is of great significance in the process of Lunan Pharmaceutical's internationalization
.
Data show that rosuvastatin calcium tablets are a selective hydroxymethylglutaryl-coenzyme A reductase inhibitor, which has the characteristics of potent hypolipidemic reduction, fast and safe
.
Hengrui Pharmaceuticals recently stated that in early October, Dr.
Joseph E.
Eid joined Hengrui's overseas team as the chief medical officer of Hengrui US/Europe, mainly responsible for Hengrui's drug development and medical affairs in the European and American regions
.
And this personnel action is considered to be Hengrui's major move to accelerate the process of internationalization
.
When confirming the news, Hengrui Pharmaceuticals stated that the company continues to increase its investment in internationalization.
At present, it has established professional clinical research and development teams in the United States, Europe, Australia, and Japan.
, GPT) mode
.
In addition, Huiyu Pharmaceutical stated that the company relies on the established international sales channels and teams to further advance and refine the work of the international market
.
The company will improve the management system of partners according to the conditions of different countries and regions, strengthen market information collection and analysis capabilities, establish the company's unique global market and a large database of partners, track the development and changes of global medicine, and fully analyze the market environment and ecology of key regions.
Operation model, deep cultivation and meticulous cultivation, to become an international pharmaceutical company
.
The global market is the direction everyone is aiming for
.
According to the industry, in recent years, China's innovative drugs have developed vigorously, which has changed innovative drugs to a large extent.
“We hope that this situation will not only happen in China, but that Chinese pharmaceuticals and bio-innovative drugs can also go to more countries.
, To benefit patients in those countries
.
" In addition, only by "going out" can pharmaceutical companies embrace a broader market
.
According to IQVIA statistics, the size of China's prescription drug market will be about 1.
2 trillion yuan in 2020, and excluding Chinese patent medicines and generic drugs will drop to 70 billion yuan
.
According to evaluate analysis, the global prescription drug market will reach US$904 billion in 2020, or about 5.
8 trillion yuan
.
"Going out is five times or even ten times the market!" Some insiders said
.
Driven by the huge market, more and more companies choose to "go global
.
" For example, in 2017, Nanjing Legend Biotech "handed in" Yang Sen to jointly develop and commercialize CAR-T cell products; in 2020, Tianjing Biotech authorized AbbVie's overseas rights and interests of CD-47 monoclonal antibody; in the same year, Jacques also Reached a cooperation agreement with AbbVie
.
In addition, Baekje, Cinda, Junshi and other companies have also authorized their PD-1 overseas commercialization rights to Novartis, Eli Lilly, Coherus and other multinational pharmaceutical companies to enter the international market
.
